ライフサイエンスコーパス: tolerability

1 selumetinib and trametinib (albeit with poor tolerability).

2 nal symptoms as well as treatment safety and tolerability.

3 The primary endpoint was safety and tolerability.

4 ageable safety profile, including acceptable tolerability.

5 d an outcome system integrating efficacy and tolerability.

6 ctives were evaluation of tumor response and tolerability.

7 ) and there were no differences in safety or tolerability.

8 of the risk for allograft rejection and poor tolerability.

9 The primary objectives were safety and tolerability.

10 eriatric patients, with excellent safety and tolerability.

11 eeks of treatment were cured, with excellent tolerability.

12 cts on disease-related symptoms, safety, and tolerability.

13 The primary endpoint was safety and tolerability.

14 profiles for optimal antitumor activity and tolerability.

15 with the reversal of anhedonia and improved tolerability.

16 in tests because negative responses indicate tolerability.

17 ) values were 33.21% for efficacy and 0% for tolerability.

18 The primary outcomes were safety and tolerability.

19 se for future studies and to evaluate safety/tolerability.

20 e primary objective was to assess safety and tolerability.

21 cancer therapeutics with improved safety and tolerability.

22 ported and because negative results indicate tolerability.

23 r-boosted darunavir once daily, with similar tolerability.

24 ients on the basis of dyskinesia control and tolerability.

25 e primary objective was to assess safety and tolerability.

26 se and network meta-analyses of efficacy and tolerability.

27 rdive dyskinesia, with favourable safety and tolerability.

28 mantle cell lymphoma (MCL), with manageable tolerability.

29 dence, an optimal dosing regimen, and better tolerability.

30 and has an established record of safety and tolerability.

31 ontrol strategies with improved efficacy and tolerability.

32 of the risk for allograft rejection and poor tolerability.

33 and also suggest good to moderate treatment tolerability.

34 inst usual treatment options and longer term tolerability.

35 ferentiated by very high efficacy but poorer tolerability.

36 ere comparable in terms of high efficacy and tolerability.

37 The primary objective was safety and tolerability 28 days post-injection.

38 robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumo

39 en-ended end-of-study feedback at 6 mo), and tolerability (acute mental health services referral).

40 rt of limited size, brexanolone demonstrated tolerability among SRSE patients of heterogeneous etiolo

41 otype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-ora

42 Primary endpoints were safety and tolerability, analysed in the all-patients-as-treated po

43 Endpoint and tolerability analyses were analyzed using meta-regressio

44 cannabidiol were included in the safety and tolerability analysis, and 137 (64%) patients were inclu

45 d not induce systemic effects, implying good tolerability and a favorable safety profile for RNAdjuva

46 We have assessed the safety, tolerability and activity of emactuzumab in patients wit

47 red with weak opioids, with a similarly good tolerability and an earlier effect.

48 A qualitative analysis of 13 studies on tolerability and comfort suggested that high-flow nasal

49 Weekly administration of bortezomib enhanced tolerability and convenience.

50 nt phase 1b trial was to evaluate the safety/tolerability and CP-blocking potential of 4 weekly doses

51 In this trial, we addressed the tolerability and efficacy of adding rituximab with or wi

52 METHOD: The authors compared the tolerability and efficacy of lithium carbonate and dival

53 We wanted to examine tolerability and efficacy of NSI-189, a benzylpiperizine

54 y study for prioritizing compounds with good tolerability and efficacy that ultimately led to the sel

55 esults can be crossed with information about tolerability and functioning to yield an outcome system

56 The primary outcomes were tolerability and GBS-specific antibody response (measure

57 50 formulation displayed the best balance of tolerability and immunogenicity.

58 one-naloxone combination in providing better tolerability and less trial withdrawal rate.

59 ce a week was chosen based on better patient tolerability and no demonstrable improvement in radiolog

60 ant tuberculosis; and (3) evaluating safety, tolerability and pharmacokinetics of tuberculosis drugs

61 Drug safety and tolerability and Plasmodium falciparum resistance-mediat

62 hat of pictilisib might be needed to improve tolerability and potentially increase efficacy.

63 plus DTIC may be a frontline option based on tolerability and response duration.

64 Tolerability and response were evaluated using hematolog

65 lated to a maximum dose of 200 mg/d based on tolerability and response) or matching placebo (n = 99).

66 roperties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was ad

67 However, drug tolerability and the evolution of drug resistance have l

68 although effective are associated with poor tolerability and the need for titration.

69 , adverse effects of statins may limit their tolerability and therefore the ability to attain effecti

70 mycophenolate mofetil because of its better tolerability and toxicity profile.

71 arable pharmacokinetics, improved safety and tolerability, and a more favorable toxicity profile when

72 nstration project that evaluated the safety, tolerability, and acceptability of TDF/FTC and patterns

73 We aimed to assess the safety, tolerability, and antitumour activity of pembrolizumab,

74 D and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the

75 expected to improve their efficacy, safety, tolerability, and duration of effect in future studies.

76 Safety, tolerability, and efficacy analyses all used a modified

77 oral DAA regimens show high rates of safety, tolerability, and efficacy for treatment of HCV genotype

78 We investigated the safety, tolerability, and efficacy of increasing doses of idaruc

79 an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir

80 ouraged investigators to explore the safety, tolerability, and efficacy of mesenchymal stromal cell-b

81 We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon afte

82 Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal an

83 We aimed to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z in Malia

84 This study tested the safety, tolerability, and initial human laboratory efficacy of I

85 clinical treatment remains unclear: safety, tolerability, and pharmacokinetic data for many tubercul

86 Safety, tolerability, and pharmacokinetic parameters were assess

87 We investigated the efficacy, tolerability, and pharmacokinetics of artefenomel at dif

88 We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested

89 The primary endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib.

90 We aimed to assess the safety, tolerability, and pharmacokinetics of long-acting cabote

91 Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.

92 nstrate the feasibility, selective toxicity, tolerability, and potential efficacy of pharmacological

93 This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral prote

94 ll survival (OS), progression-free survival, tolerability, and quality of life.

95 The primary endpoints were the safety, tolerability, and recommended phase 2 dose of PF-0413630

96 We aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the C

97 d on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing

98 s mitochondrial energy; however, its safety, tolerability, and therapeutic effect on cardiac structur

99 Tolerability as measured by neurocognitive performance (

100 sing clinical and laboratory parameters, and tolerability as rated by the Gastrointestinal Symptom Ra

101 The primary outcome was safety and tolerability, assessed in all treated patients.

102 The primary endpoint was safety and tolerability, assessed with recording adverse events, se

103 ting plasma Lp(a) concentration, safety, and tolerability at day 30 in the single-ascending-dose phas

104 igher doses are somewhat offset by decreased tolerability at high doses.

105 Safety, tolerability, birch-pollen-specific immunoglobulin level

106 ycodone-naloxone are found to exhibit better tolerability characteristics in comparison with other op

107 Primary end points were safety and tolerability; clinical activity and immune activation we

108 noninferior therapeutic efficacy and similar tolerability compared to triple therapy.

109 ed with both benefit in time manic and worse tolerability compared with placebo.

110 is efficacious for chorea control; however, tolerability concerns exist.

111 No safety or tolerability concerns were reported.

112 m of action, clinical trial data, safety and tolerability concerns, and monitoring requirements.

113 amatically improved preclinical efficacy and tolerability data were generated for the pamoic acid lea

114 efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events).

115 A combined tolerability, dose-finding study with a sublingual liqui

116 ical antipsychotic drugs (APDs), with better tolerability due to more selective dopamine (DA) recepto

117 Lipids, safety, and tolerability every 12 weeks.

118 The main safety and tolerability findings are amyloid-related imaging abnorm

119 Cohort expansion was based on safety and tolerability, FLT3 inhibition in correlative assays, and

120 In terms of tolerability, fluoxetine was also better than duloxetine

121 provided the best visual acuity results and tolerability for all working distances.

122 howed comparable immunogenicity, safety, and tolerability for both vaccines.

123 l drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV).

124 d maintain survival outcomes while improving tolerability for patients with HPV-positive oropharyngea

125 Primary endpoints were safety and tolerability for the escalation phase and objective resp

126 The primary endpoint was safety and tolerability from the first injection (week 5) to 12 wee

127 vidence-based therapies are often limited by tolerability, hypotension, electrolyte disturbances, and

128 Secondary end points included toxicity, tolerability, imaging response using volumetric magnetic

129 ation, scripted interaction), and safety and tolerability in a multicenter, randomized, double-blind,

130 birch pollen allergen, showed good clinical tolerability in a previous phase I/IIa clinical trial.

131 promising clinical efficacy with acceptable tolerability in chemotherapy-naive PDAC patients with pe

132 promising clinical efficacy with acceptable tolerability in chemotherapy-naive PDAC patients with pe

133 zumab has antitumour activity and acceptable tolerability in cisplatin-ineligible patients with uroth

134 er multiple outcomes related to efficacy and tolerability in combination for each treatment.

135 phase I clinical trials to assess safety and tolerability in healthy human subjects prior to the init

136 doses without titration, and has shown good tolerability in healthy individuals in phase 1 studies.

137 has demonstrated high efficacy, safety, and tolerability in hepatitis C virus (HCV)-infected patient

138 stability in liver microsomes, and improved tolerability in mice.

139 This study assesses its safety and tolerability in nonuremic type 1 diabetic recipients.

140 has been shown to significantly enhance drug tolerability in patients as compared to the conventional

141 We assessed its safety and tolerability in patients with advanced breast and gastri

142 ating a high level of efficacy and favorable tolerability in patients with HCV infection.

143 has durable clinical activity and favourable tolerability in patients with relapsed or refractory chr

144 le solubility compared to 29 and showed good tolerability in preclinical species.

145 icacy in reducing negative symptoms and good tolerability in stable schizophrenia patients.

146 than six doses of study drug) and safety and tolerability in the safety population.

147 tor that demonstrated favorable efficacy and tolerability in the treatment of tardive dyskinesia in p

148 tezolizumab showed durable activity and good tolerability in this patient population.

149 The primary endpoint was safety and tolerability, including adverse events, non-haematologic

150 If no tolerability issues arose by day 14, the starting dose,

151 aches have limitations, including pain, poor tolerability, lack of adherence, and inadequate delivery

152 L) amyloidosis were to determine the safety, tolerability, maximum tolerated dose (MTD), recommended

153 ry endpoint measure), and other efficacy and tolerability measures.

154 d on patient preferences, comorbidities, and tolerability might be possible.

155 We assessed the efficacy, safety, and tolerability of 12 weeks of combination therapy with led

156 parallel design, we tested the efficacy and tolerability of 4-wk intranasal OXT treatment (24 Intern

157 The safety and tolerability of a mite allergoid subcutaneous allergen i

158 We assessed the safety and tolerability of a newly developed photosensitiser, disul

159 is study was to evaluate the response to and tolerability of a single dose of (177)Lu-PSMA-617 in a l

160 ve of the study was to assess the safety and tolerability of a single intravitreous injection of AAV2

161 We tested the safety and tolerability of a single intravitreous injection of an A

162 The PANORAMA study assessed the safety and tolerability of acetylcysteine combined with pirfenidone

163 determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in

164 To evaluate the safety and tolerability of and clinical response to a single, subre

165 present proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in advanced cer

166 Assessments of safety and tolerability of AZD3241 included records of adverse even

167 The goal of this study was to test the tolerability of bacteria on the ocular surface using in

168 Here, we evaluated the efficacy and tolerability of blinatumomab in patients with relapsed o

169 in SRSE patients to evaluate the safety and tolerability of brexanolone (USAN; formerly SAGE-547 Inj

170 The efficacy, safety, and tolerability of brexpiprazole and placebo were compared

171 ry objective was to establish the safety and tolerability of cannabidiol and the primary efficacy end

172 authors evaluated the efficacy, safety, and tolerability of cariprazine, an atypical antipsychotic c

173 We aimed to assess the efficacy, safety, and tolerability of ceftazidime-avibactam compared with best

174 ary endpoints of the studies were safety and tolerability of combining idelalisib with lenalidomide a

175 rly (PRIDE) study evaluated the efficacy and tolerability of continuation ECT plus medication compare

176 Efficacy and tolerability of conventional oral iron supplements are m

177 to evaluate the efficacy, safety, and local tolerability of diclofenac HPbetaCD administered as a lo

178 rall indicate efficacy, safety, and relative tolerability of diclofenac HPbetaCD used locally as a su

179 echanism of action as well as the safety and tolerability of drugs in pediatric patients, including c

180 andomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-

181 ne therapy trial to determine the safety and tolerability of escalated doses of an adeno-associated v

182 e of this study was to assess the safety and tolerability of evolocumab in a pooled safety analysis f

183 We aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel

184 e I clinical trial evaluating the safety and tolerability of human parthenogenetic stem cell derived

185 ld be investigated to improve the safety and tolerability of immunotherapy.

186 sought to evaluate the efficacy, safety, and tolerability of intradermally administered grass allerge

187 To evaluate the clinical efficacy and tolerability of intravenous (i.v.) and intraperitoneal (

188 We assessed the efficacy, safety, and tolerability of lacosamide as a first-line monotherapy o

189 ), ocular discomfort score (ODS), and safety/tolerability of lifitegrast versus placebo.

190 esults demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with

191 sed to improve the selectivity, efficacy and tolerability of LTCC antagonists.

192 port both the long-term clinical benefit and tolerability of maintenance olaparib in patients with BR

193 s for improved disease control and increased tolerability of medications, and also presents new safet

194 e authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for

195 104 was designed to evaluate the safety and tolerability of multiple doses of VRC01 administered eit

196 To assess the safety and tolerability of MVC-containing PrEP over 48 weeks in U.S

197 y is to investigate the pharmacokinetics and tolerability of NSC23925b, a novel and potent P-glycopro

198 The safety and tolerability of ocriplasmin were evaluated.

199 The adverse event profile and tolerability of OM were similar to those of placebo, wit

200 nd older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in sev

201 Aim of this study was to study the tolerability of opioid analgesia by performing a network

202 is study evaluates the efficacy, safety, and tolerability of regimens containing sofosbuvir (SOF) in

203 y objective is to investigate the safety and tolerability of repeat doses of GSK2330672, and explore

204 The primary objective was safety and tolerability of RG-101.

205 ndings suggest an improved effectiveness and tolerability of rituximab compared with fingolimod in st

206 Future studies should optimize efficacy and tolerability of salvage therapy by stratifying patients

207 Conclusion These data show activity and tolerability of savolitinib in the subgroup of patients

208 centre trial evaluated the dose-response and tolerability of SB.

209 TGF-beta1/3, demonstrating the efficacy and tolerability of selective TGF-beta ligand blockade for i

210 We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with p

211 ort on the virological response, safety, and tolerability of SOF and SMV with or without RBV in compe

212 he effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder.

213 o assess the feasibility, acceptability, and tolerability of storytelling among bereaved surrogates i

214 ty with cephalosporins and aztreonam and the tolerability of such alternative beta-lactams, all subje

215 We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen con

216 med to investigate the efficacy, safety, and tolerability of switching to this regimen compared with

217 daily for 4 to 6 weeks) to ensure short-term tolerability of the 2 study medications.

218 R8 activity, which may be detrimental to the tolerability of the candidate drug.

219 The issue lies on the poor tolerability of the standard of care soluble iron salts,

220 at the end of treatment were the safety and tolerability of the treatment regimen, analysed in the i

221 Questionnaire (MiniRQLQ) results and safety/tolerability of the treatment were assessed.

222 The primary outcome was the safety and tolerability of the vaccine, assessed as local and syste

223 once daily), and to evaluate the safety and tolerability of these combination regimens in individual

224 basis of the PFS, overall response rate, and tolerability of these two antivascular therapies, furthe

225 ry end points of the studies were safety and tolerability of this cell therapy.

226 sed studies have investigated the safety and tolerability of this combination.

227 We assessed the tolerability of this early administration of MMR vaccine

228 oke prompted investigation of the safety and tolerability of this treatment in stroke patients.

229 The safety and tolerability of tiotropium were comparable with those of

230 The primary endpoints were safety and tolerability of TPCS2a; other co-primary endpoints were

231 In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previo

232 We aimed to assess the efficacy, safety, and tolerability of two unique antisense oligonucleotides de

233 availability, cost effectiveness and better tolerability of ultrasonography make it a modality of fi

234 further evaluated the efficacy, safety, and tolerability of valbenazine as a treatment for tardive d

235 Given the superior tolerability of venetoclax, here we have investigated it

236 te and normal groups differ substantially in tolerability or pharmacokinetics.

237 Depending on tolerability, patients were then assigned to nivolumab 1

238 el phase III trial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaft

239 RP2D) was determined on the basis of safety, tolerability, pharmacokinetics (PK), and by mRNA express

240 in healthy human subjects evaluated safety, tolerability, pharmacokinetics and sleep-promoting effec

241 ethods The primary objectives were to assess tolerability, pharmacokinetics, and activity.

242 m of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of

243 dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of

244 We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759

245 s first-in-human study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of

246 tion study was conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of

247 This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of

248 We aimed to compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of

249 s of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended

250 On the basis of safety, tolerability, PK, and PD, the RP2D was established at 40

251 inumab regimens had an acceptable safety and tolerability profile but did not significantly reduce as

252 s long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previous

253 tuzumab vedotin has an acceptable safety and tolerability profile in patients with NHL but not in tho

254 primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor ag

255 The safety and tolerability profile of CUDC-907 and the promising preli

256 pirfenidone does not substantially alter the tolerability profile of pirfenidone, and is unlikely to

257 ith a low incidence of PTDM and a manageable tolerability profile over 24 weeks of treatment.

258 lus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumour activity irrespect

259 he p53 pathway with an acceptable safety and tolerability profile.

260 ar function and corneal status and a similar tolerability profile.

261 C compared with gefitinib, with a manageable tolerability profile.

262 vaccine was generally safe with a reasonable tolerability profile.

263 Tolerability profiles were comparable between arms.

264 tent preclincal efficacy as well as improved tolerability relative to current agents that target the

265 losis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifa

266 ated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in patients wit

267 s no significant difference in the composite tolerability scores between the 2 groups (P = 0.06).

268 s for switching therapy include convenience, tolerability, simplification, anticipation of potential

269 r potency, defined chemical nature, and good tolerability, SNAs are attractive new modalities for dev

270 and evaluated in murine pharmacokinetic and tolerability studies.

271 Phase 2 48-week safety/tolerability study was conducted, comparing 4 regimens:

272 raging durable response rates, survival, and tolerability, supporting its therapeutic use in untreate

273 raging durable response rates, survival, and tolerability, supporting its therapeutic use in untreate

274 Secondary end points included tolerability, systemic hypotension and intracranial hype

275 well tolerated with better gastrointestinal tolerability than dolutegravir, abacavir, and lamivudine

276 To assess safety and tolerability, the first 60 participants were given sertr

277 Secondary objectives included safety and tolerability, time to progression, progression-free surv

278 series of PPI-related DHR, followed up their tolerability to alternative anti-ulcer agents, and inves

279 potential risk of cross-hypersensitivity or tolerability to other PPI after their hypersensitivity e

280 s (time to next therapy >/=3 years) and good tolerability to previous regimen.

281 Subjective measures including tolerability to sun exposure, ability to participate in

282 ty in the corresponding phenotypes and least tolerability to variation: ABAT, KIAA2022, COL4A1, CACNA

283 , treatment-emergent mania or hypomania, and tolerability (using dropout rates as a proxy).

284 ment in progression-free survival and better tolerability versus temsirolimus in patients with relaps

285 These findings combined with good tolerability warrant further investigation with this com

286 Tolerability was assessed based on a measure of sedation

287 Tolerability was assessed based on subject reports of di

288 Safety and tolerability was assessed through 28 days post-dose 4.

289 The primary endpoint of safety and tolerability was not met.

290 were no new or long-term safety concerns and tolerability was similar across groups (neoadjuvant and

291 To establish their relative efficacy and tolerability, we searched MEDLINE, PubMed, Embase, and C

292 Safety and tolerability were also evaluated.

293 Safety and tolerability were assessed at all visits.

294 Safety and tolerability were assessed by monitoring adverse events,

295 Safety and tolerability were assessed in the safety analysis set (a

296 imed to assess whether efficacy, safety, and tolerability were non-inferior in patients switched to a

297 tic as monotherapy but demonstrate favorable tolerability, which has prompted interest in combination

298 The lower dose may allow for better tolerability while maintaining efficacy.

299 ertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (I

300 The primary objective was safety and tolerability, with severity of adverse events assessed w